Yuvraj

Accelerate pharmaceutical R&D decision-making by implementing modern governance frameworks that establish clear decision rights, defined escalation pathways and cross-functional ownership while maintaining strategic alignment and rigor.

Novartis, which is a leading global innovative medicines company, went ahead and announced on December 19, 2025, that it has reached an agreement along with...

President Donald Trump on December 19, 2025, said that his administration has reached agreements with nine additional pharmaceutical companies, therefore extending a campaign that...

The U.S. Food and Drug Administration – FDA on December 22, 2025, gave an approval to the first GLP-1 pill for obesity from Novo Nordisk,...

Job markets today are transforming rapidly. In the past few years, we have experienced a paradigmatic shift in the way we work, with the...

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.